CSPC PHARMA (01093) announced that its subsidiary, CSPC Innovation, recorded revenue of RMB 665 million in the first quarter of 2026, representing a year-on-year increase of 40.82%. However, the net loss attributable to shareholders reached RMB 93.8547 million, a significant expansion of 248.88% compared to the same period last year. The basic loss per share was RMB 0.0674.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments